These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Protection against Schistosoma haematobium infection in hamsters by immunization with Schistosoma mansoni gut-derived cysteine peptidases, SmCB1 and SmCL3.
    Author: Tallima H, Abou El Dahab M, Kareem S, Dalton JP, El Ridi R.
    Journal: Vaccine; 2017 Dec 15; 35(50):6977-6983. PubMed ID: 29122387.
    Abstract:
    We examined the immunogenicity and protective potential of SmCB1 and SmCL3 cysteine peptidases, alone and in combination, in hamsters challenged with S. haematobium. For each of two independent experiments, eight Syrian hamsters were immunized twice with a three week-interval with 0 (controls), 20 µg SmCB1, 20 µg SmCL3, or 10 µg SmCB1 plus 10 µg SmCL3, and then percutaneously exposed eight weeks later to 100 S. haematobium cercariae. Hamsters from each group were assessed for humoral and whole blood culture cytokine responses on day 10 post challenge infection, and examined for parasitological parameters 12 weeks post infection. At day 10 post-infection we found that SmCB1 and SmCL3 elicited low antibody titres and weak but polarized cytokine type 2 responses. Nevertheless, both cysteine peptidases, alone or in combination, evoked reproducible and highly significant reduction in challenge worm burden (>70%, P < 0.02) as well as a significant reduction in worm egg counts and viability. The data support our previous findings and show that S. mansoni cysteine peptidases SmCB1 and SmCL3 are efficacious adjuvant-free vaccines that induce protection in mice and hamsters against both S. mansoni and S. haematobium.
    [Abstract] [Full Text] [Related] [New Search]